Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms.
Recent evidence from in vitro and in vivo studies has demonstrated that aberrant reactivation of the Sonic Hedgehog (SHH) signaling pathway regulates genes that promote cellular proliferation in various human cancer stem cells (CSCs). Therefore, the chemotherapeutic agents that inhibit activation of...
Main Authors: | Brahma N Singh, Junsheng Fu, Rakesh K Srivastava, Sharmila Shankar |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2011-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3210776?pdf=render |
Similar Items
-
Sonic hedgehog signaling inhibition provides opportunities for targeted therapy by sulforaphane in regulating pancreatic cancer stem cell self-renewal.
by: Mariana Rodova, et al.
Published: (2012-01-01) -
Inhibition of CAL27 Oral Squamous Carcinoma Cell by Targeting Hedgehog Pathway With Vismodegib or Itraconazole
by: Raíza Dias Freitas, et al.
Published: (2020-11-01) -
EGCG enhances the therapeutic potential of gemcitabine and CP690550 by inhibiting STAT3 signaling pathway in human pancreatic cancer.
by: Su-Ni Tang, et al.
Published: (2012-01-01) -
Resveratrol inhibits growth of orthotopic pancreatic tumors through activation of FOXO transcription factors.
by: Sanjit K Roy, et al.
Published: (2011-01-01) -
Embelin suppresses growth of human pancreatic cancer xenografts, and pancreatic cancer cells isolated from KrasG12D mice by inhibiting Akt and Sonic hedgehog pathways.
by: Minzhao Huang, et al.
Published: (2014-01-01)